URL Pharma is a leading specialty pharmaceutical company committed to developing and commercializing safe, effective, and innovative medications and technologies that make a meaningful difference in the lives of patients and provide physicians with treatment options that greatly enhance patient care.
URL Pharma has more than 60 years of operating history, is highly profitable, and has a diversified product portfolio including a deep, mid-to-late-stage branded product and technology pipeline.
The Company’s COLCRYS®, FIBRICOR®, Qualaquin® products, and other licensing deals are expected to be the most important areas of growth for the company. We also expect to commercialize several mid-to-late stage NDA products over the next 5 years.
Branded development initiatives are focused on products that address unmet medical needs and provide value for patients and payers. Branded products are commercialized via URL Pharma’s internal capabilities, partnerships, or licensing agreements. URL Pharma has also developed multiple technologies for drug delivery and product enhancement including NanoBurst™,Z-Burst™, and MultiBurst™ technologies. For more information on these technologies, please click here.
Most of our initiatives have intellectual property or regulatory protection. In mid 2009, URL Pharma’s patent portfolio included multiple approved US patents and almost 70 patent applications awaiting approval.